Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations: Table 1

30 Aug 2010

Abstract excerpt

INTRODUCTION: The Li-Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages. Basal (triple negative) breast cancers are now well recognised to be a typical sub-type of breast cancer developing in a large proportion of BRCA1 gene carriers. We considered whether a similar narrow sub-type of breast cancer was found in TP53 gene mutation carriers....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Cancer-related Molecular Pathways
Share to Cancer Risks and Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20805372
DOI: 10.1136/jmg.2010.078113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations: Table 1PMID 20805372Read ↗

Early onset HER2-positive breast cancer is associated with germline TP53 mutations.Semantic proximity Read ↗

Apparently "BRCA-related" breast and ovarian cancer patient with germline TP53 mutation.Semantic proximity Read ↗

Clinical implications of germline mutations in breast cancer: TP53.Semantic proximity Read ↗

Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.Semantic proximity Read ↗

Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.Semantic proximity Read ↗

Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)Semantic proximity Read ↗

Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.Semantic proximity Read ↗

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.Semantic proximity Read ↗

Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.Semantic proximity Read ↗

The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.Semantic proximity Read ↗

Prediction of pathogenic mutations in patients with early-onset breast cancer by family history.Semantic proximity Read ↗

BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.